When will CagriSema be approved and available in the US?

CagriSema is a treatment for obesity in development from Novo Nordisk. It is a fixed-dose combination of the GLP-1 agonist semaglutide (2.4 mg) and cagrilintide (2.4 mg), a long-acting amylin analogue. It helps you lose weight by reducing appetite, slowing gastric emptying, and lowering blood glucose levels. Novo Nordisk originally planned on seeking approval at the end of this year, but that has been pushed back to early 2026. This is to be sure their supply chain is fully prepared to handle the launch.
Given the regulatory process and review timelines from the FDA, you can expect CagriSema to be on the US market sometime in 2027.